ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biologics"

  • Abstract Number: 1678 • 2015 ACR/ARHP Annual Meeting

    Does the Level of Disease Control Achieved with Biologics Influence Overall Costs for Health Care and Work Loss in RA?

    Jonas K Eriksson1, Martin Neovius2, Johan Askling3 and ARTIS study group, 1Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 2Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, 3Rheumatology Unit, Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose: Numerous studies have modeled whether biologic drugs are good value for money in the treatment of RA, in terms of reducing health care use…
  • Abstract Number: 2783 • 2015 ACR/ARHP Annual Meeting

    What Is the Rate of Primary and Secondary Failure of Anti-TNF in RA Patients? Data from a Rheumatoid Arthritis Cohort

    Edward C. Keystone1, Mohammad Movahedi2,3, Angela Cesta2, Xiuying Li2, Sandra Couto2, Emmanouil Rampakakis3, John S. Sampalis3,4, Claire Bombardier2,5,6 and OBRI Investigators, 1The Rebecca MacDonald Centre For Arthritis, Mount Sinai Hospital, Toronto, ON, Canada, 2Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 3JSS Medical Research, St-Laurent, QC, Canada, 4McGill University, Montreal, QC, Canada, 5University of Toronto, Department of Medicine (DOM) and Institute of Health Policy Management, and Evaluation (IHPME), Toronto, ON, Canada, 6Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada

    Background/Purpose: Although the majority of RA patients respond to treatment with anti-TNF agents, some patients present with refractory disease (1ry failure) while others show some…
  • Abstract Number: 603 • 2015 ACR/ARHP Annual Meeting

    Which Seronegative RA Patients Respond to Rituximab? – Preliminary Analysis of a Merged Clinical Trials Dataset

    Elizabeth M.A. Hensor1,2, Edward M. Vital1,2 and Paul Emery1,2, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Background/Purpose: Seronegative RA patients have inferior clinical response to rituximab [1].  However, there is significant heterogeneity in this group of patients for baseline clinical features…
  • Abstract Number: 1997 • 2015 ACR/ARHP Annual Meeting

    Underuse of Methotrexate (MTX) in the Treatment of Rheumatoid Arthritis (RA) in the United States (US): Results of a Comprehensive Pharmaceutical Claims Analysis

    James R. O'Dell1, Melanie Rohr1, Stanley B. Cohen2, J Carter Thorne3 and Ted R. Mikuls1, 1University of Nebraska Medical Center, Omaha, NE, 2Metroplex Clinical Research Center, Dallas, TX, 3Southlake Regional Health Centre, Newmarket, ON, Canada

    Background/Purpose: MTX is the anchor DMARD for RA treatment, but there is limited information about its appropriate use in clinical practice. This claims analysis was…
  • Abstract Number: 2841 • 2015 ACR/ARHP Annual Meeting

    Changes in Treatment Patterns in Psoriatic Arthritis Patients Newly Initiated on Biologic and Non-Biologic Therapy Enrolled in a North American Clinical Registry

    Philip J. Mease1, Tamara Lesperance2, Neil Accortt2, David Collier2, Mei Liu3, Marc Mason4 and Sabrina Deveikis4, 1Clinical Professor, University of Washington School of Medicine, Seattle, WA, 2Amgen, Inc., Thousand Oaks, CA, 3352 Turnpike Rd, Corrona, LLC, Southborough, MA, 4Corrona, LLC., Southborough, MA

    Background/Purpose: Over the past decade, the treatment of PsA has improved significantly. The purpose of this study was to describe real-world treatment patterns among PsA…
  • Abstract Number: 610 • 2015 ACR/ARHP Annual Meeting

    Risk of Herpes Zoster in Patients with Rheumatoid Arthritis Treated with Biologic Disease-Modifying Therapy Compared with Conventional Therapy

    Hyun Mi Kwon, Sang Jin Lee, Ji Ae Yang, Jin Young Moon, Eun Young Ahn, Jin Kyun Park, Eun Young Lee, Yeong Wook Song and Eun Bong Lee, Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea

    Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for herpes zoster (HZ) infection. RA treatment including immunosuppressant medications could further exacerbate the risk.…
  • Abstract Number: 2038 • 2015 ACR/ARHP Annual Meeting

    Adalimumab in Patients with Active, Noninfectious Uveitis Using High-Dose Corticosteroids

    Antoine P. Brezin1, Phillippe Kestelyn2, Joachim Van Calster3, Glenn J. Jaffe4, Jennifer E. Thorne5, David Scales6, Pablo Franco7, Andrew D. Dick8,9,10, Quan Dong Nguyen11, Eric B. Suhler12,13, Anne Camez14, Alexandra P. Song15, Martina Kron14, Samir Tari15, James T. Rosenbaum16,17 and Arnd Heiligenhaus18, 1Université Paris Descartes, Hôpital Cochin, Paris, France, 2Ghent University Hospital, Ghent, Belgium, 3University Hospitals Leuven, Leuven, Belgium, 4Duke University, Durham, NC, 5Johns Hopkins Medical Institute, Baltimore, MD, 6University of Texas Health Science Center, San Antonio, TX, 7Organización Médica de Investigación (OMI), Buenos Aires, Argentina, 8National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital, London, United Kingdom, 9University of Bristol, Bristol Eye Hospital, Bristol, United Kingdom, 10University College London, Institute of Ophthalmology, London, United Kingdom, 11Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, 12VA Portland Health Care System, Portland, OR, 13Casey Eye Institute, Oregon Health & Science Univ, Portland, OR, 14Abbvie Deutschland GmbH & Co KG, Ludwigshafen, Germany, 15AbbVie Inc., North Chicago, IL, 16Devers Eye Institute, Legacy Hospital system, Portland, OR, 17Casey Eye Institute, Oregon Health & Science University, Portland, OR, 18Department of Ophthalmology at St. Franziskus Hospital Muenster, University of Duisberg-Essen, Muenster, Germany

    Background/Purpose: Corticosteroids, currently the mainstay of uveitis treatment, are associated with adverse events and are not always fully effective. Multiple reports describe the use of…
  • Abstract Number: 2853 • 2015 ACR/ARHP Annual Meeting

    Secukinumab Improves Skin Symptoms and Physical Functioning Compared with Ustekinumab in Patients with Moderate to Severe Psoriasis with Concomitant Psoriatic Arthritis: Subanalysis of a Randomized, Double Blind, Parallel-Group, Active Comparator-Controlled Phase 3b Trial

    Alice B. Gottlieb1, Diamant Thaci2, Andrew Blauvelt3, Marina Milutinovic4 and Shephard Mpofu4, 1Tufts Medical Center and Tufts University School of Medicine, Boston, MA, 2Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany, 3Research Excellence & Personalized Patient Care, Oregon Medical Research Center, Portland, OR, 4Novartis Pharma AG, Basel, Switzerland

    Background/Purpose: Psoriatic arthritis (PsA) is a common comorbidity in patients (pts) with psoriasis. In the ongoing Phase 3b CLEAR study (NCT02074982), secukinumab, a fully human…
  • Abstract Number: 617 • 2015 ACR/ARHP Annual Meeting

    Biological Down-Titration in RA: Patient Profile and Response to Retreatment in Flaring Patients

    Juan P. Vinicki1, Miguel Arredondo1, Esther Ramirez2, Ana M. Ortiz Garcia3, Santos Castañeda4, Alberto Morell1, Rosario Garcia-Vicuña3 and Jose María Alvaro-Gracia4, 1Unidad de Terapias Biológicas, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 2Farmacia, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 3Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 4Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain

    Background/Purpose: Down-titration of biological therapy (BT) in rheumatoid arthritis (RA) patients with a good clinical response is frequently applied in daily clinical practice. An important…
  • Abstract Number: 2052 • 2015 ACR/ARHP Annual Meeting

    Lymphoma in Patients with Rheumatoid Arthritis Treated with Biologic Drugs:  Long-Term Follow-up of Risks and Lymphoma Subtypes

    Karin Hellgren1, Christer Sundström2, Johan Askling3, Eva Baecklund4 and on behalf of the ARTIS study group, 1Clinical Epidemiology Unit and Rheumatology Unit, Department of Medicine, Karolinska Institute at Karolinska University Hospital, Stockholm, Sweden, 2Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden, 3Clinical Epidemiology Unit and Rheumatology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, 4Rheumatology, Department of Medical Sciences, University Hospital, Uppsala, Sweden

    Background/Purpose: The long-term lymphoma risk in patients with rheumatoid arthritis (RA) treated with biologic disease modifying anti-rheumatic drugs (bDMARDs) remains a concern. The aim of…
  • Abstract Number: 2903 • 2015 ACR/ARHP Annual Meeting

    Late-Onset Neutropenia Following Rituximab Treatment in Patients with Systemic Lupus Erythematosus

    Ioannis Parodis, Frida Söder, Ronald F. van Vollenhoven, Elisabet Svenungsson and Iva Gunnarsson, Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: The incidence and clinical consequences of rituximab-mediated late-onset neutropenia (LON) have been studied in various diseases, but data from Systemic Lupus Erythematosus (SLE) are…
  • Abstract Number: 50 • 2015 ACR/ARHP Annual Meeting

    Characteristics and Outcomes Associated with Early Corticosteroid Use in a Large Multicenter Canadian RA Cohort

    Kathleen Andersen1, Daming Lin2, Susan J. Bartlett3,4, Gilles Boire5, Boulos Haraoui6, Carol Hitchon7, Shahin Jamal8, Edward C. Keystone9, Janet E. Pope10, Diane Tin11, J Carter Thorne12, VP Bykerk13,14 and CATCH Investigators, 1Hospital for Special Surgery, New York, NY, 2Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 3Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, 4Medicine , Divisions of Clinical Epidemiology, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, 5Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, 6Institut de Rhumatologie, Montreal, QC, Canada, 7Department of Rheumatology, University of Manitoba, Winnipeg, MB, Canada, 8Vancouver Coastal Health, Vancouver, BC, Canada, 9Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 10University of Western Ontario, London, ON, Canada, 11The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 12University of Toronto, Toronto, ON, Canada, 13Rheumatology, Hospital for Special Surgery, New York, NY, 14Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada

    Background/Purpose: Synthetic glucocorticoids (steroids) are commonly used in RA to rapidly inhibit pro-inflammatory cytokines. They are frequently used as "bridge therapy", quickly dampening down the…
  • Abstract Number: 705 • 2015 ACR/ARHP Annual Meeting

    Sex Differences in Psoriatic Arthritis: Evaluation of a Real-Life Cohort of 2,118 Italian Patients Treated with Methotrexate

    Carlo Selmi1,2, Elena Generali3, Greta Carrara4, Carlo Alberto Scirè4 and RECORD Study Group of the Italian Society for Rheumatology, 1BIOMETRA Department, University of Milan, Milan, Italy, 2Internal Medicine- Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano, Italy, 3Internal Medicine- Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano (MI), Italy, 4Epidemiology Unit – Italian Society for Rheumatology (SIR), Milano, Italy

    Background/Purpose: The influence of sex in psoriatic arthritis (PsA) features and treatment outcomes has not been fully elucidated. We investigated the differences between sexes in…
  • Abstract Number: 2058 • 2015 ACR/ARHP Annual Meeting

    Efficacy and Safety of Rituximab Biosimilar Candidate (CT-P10) and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase I Randomized Controlled Trial over 72 Weeks

    Dae-Hyun Yoo1, Won Park2, Chang-Hee Suh3, Seung-Cheol Shim4, Slawomir Jeka5, Fidencio Cons Molina6, Pawel Hrycaj7, Wolfgang Spieler8, Piotr Wiland9, Jan Brzezicki10, Eun Young Lee11, Francisco G. Medina-Rodriguez12, Pavel Shesternya13, Sebastiao Radominski14, Marina Stanislav15, Volodymyr Kovalenko16, Donghyuk Sheen17, Leysan Myasoutova18, Mie Jin Lim19, Jung-Yoon Choe20, Taek S. Kwon21 and Sang Joon Lee21, 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, 3Department of Rheumatology, Ajou University Hospital, Suwon, South Korea, 4Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, 5University Hospital Nr 2 Dr. Jan Biziel, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Clinic of Rheumatology and Connective Tissue Diseases, Bydgoszcz, Poland, 6Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, 7Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland, 8Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, 9Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, 10Wojewodzki Szpital Zespolony w Elablagu, Elblag, Poland, 11Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, 12Rheumatology, LaSalle University, Mexico City, Mexico, 13Rheumatology Department, Krasnoyarsk State Medical University, Krasnoyarsk, Russia, 14CETI-Centro de estudos em Terapias Inovadoras, Universidade Federal do Parana, Curitiba, Brazil, 15Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russia, 16Section of Non-coronarogenic Myocardial Diseases and Clinical Rheumatology, National Scientific Center, Kiev, Ukraine, 17Rheumatology, Eulji University Hospital, Daejeon, South Korea, 18City Reumatology Center, Research Medical Complex Vashe Zdorovie, Kazan, Russia, 19Division of Rheumatology, Departments of Internal Medicine, Inha University Hospital, Incheion, South Korea, 20Internal Medicine, Catholic University of Daegu, School of Medicine, Daegu, South Korea, 21CELLTRION, Inc., Incheon, South Korea

    Background/Purpose: CT-P10 is a biosimilar candidate of innovator rituximab (RTX). PK profile and clinical data up to week 24 has been reported at ACR 20131.…
  • Abstract Number: 3171 • 2015 ACR/ARHP Annual Meeting

    Combination Therapy with Denosumab and Biologic DMARD Associated with Higher Risk of Serious Infections Compared to Denosumab Alone and Biologic DMARD Alone

    Ivana Parody1, Luis Arias-Urdaneta2, Ricardo Garcia Alemany2 and Carlos Sesin2, 1Internal Medicine, Mount Sinai Medical Center, Miami Beach, FL, 2Vanguard Rheumatology Partners, Miami Beach, FL

    Background/Purpose: Patients with RA and other rheumatologic disorders are at increased risk for osteoporotic fractures. Biologic DMARDs are an important treatment option for these patients.…
  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • …
  • 29
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology